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Abstract
Background: Posaconazole is a novel antifungal drug for
oral application intended especially for therapy of invasive
mycoses. Due to variable gastrointestinal absorption, adverse
side effects, and suspected drug-drug interactions, therapeu-
tic drug monitoring (TDM) of posaconazole is recommended.
Method: A fast ultra performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) method for
quantification of posaconazole with a run-time -3 min was
developed and compared to a LC-MS/MS method and HPLC
method with fluorescence detection.
Results: During evaluation of UPLC-MS/MS, two earlier
eluting peaks were observed in the MRM trace of posaco-
nazole. This was only seen in patient samples, but not in
spiked calibrator samples. Comparison with LC-MS/MS dis-
closed a significant bias with higher concentrations measured
by LC-MS/MS, while UPLC-MS/MS showed excellent
agreement with the commercially available HPLC method.
In the LC-MS/MS procedure, comparably wide and left side
shifted peaks were noticed. This could be ascribed to in-
source fragmentation of conjugate metabolites during elec-
trospray ionisation. Precursor and product ion scans
confirmed the assumption that the additional compounds are
posaconazole glucuronides. Reducing the cone voltage led to
disappearance of the glucuronide peaks. Slight modification
of the LC-MS/MS method enabled separation of the main
interference, leading to significantly reduced deviation.
Conclusions: These results highlight the necessity to reliably
eliminate interference from labile drug metabolites for cor-
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rect TDM results, either by sufficient separation or selective
MS conditions. The presented UPLC-MS/MS method pro-
vides a reliable and fast assay for TDM of posaconazole.
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Introduction
Triazole compounds are an established and effective class of
antifungal drugs and are suited especially for therapy of sys-
temic and superficial fungal infestations. Triazoles affect
ergosterol biosynthesis of yeasts and fungi by specific inhi-
bition of 14a-demethylase (CYP51). Indications for thera-
peutic drug monitoring (TDM) comprise non-linear
pharmacokinetics, high intra-individual metabolic variability,
narrow therapeutic range, unexpected toxicity, and possible
drug interactions (1–3). For triazole antifungals with an
approval date before 2005, TDM methods have been devel-
oped for itraconazole and its main active metabolite,
hydroxyitraconazole (4–7), as well as for voriconazole
(8–11).
Posaconazole (Noxafil), a new antimycotic triazole drug
for oral applications (Figure 1), was approved in 2005 in
Europe and 2006 in the USA. Posaconazole is intended for
therapy and prophylaxis of systemic and invasive mycoses,
particularly in patients with impaired immune function due
to immunosuppression, AIDS, or radiation therapy w(12, 13),
and commentx. Posaconazole is suited especially for treat-
ment of Candida and Aspergillus (14), but in contrast to
itraconazole, it is also effective in cases with rare mycoses,
such as fusarium (15) or zygomycetes (16). However, it has
been reported that side effects are higher when compared to
other triazoles (17, 18). TDM of posaconazole has been rec-
ommended when drug-drug interactions are suspected (2),
and a clinical trial showed that higher posaconazole concen-
trations were associated with a higher number of responders
to treatment of aspergillosis (14). Moreover, posaconazole
metabolism shows pronounced individual variability of
38%–82% in cohorts of severely ill patients (1, 5, 19). These
variations have been ascribed primarily to differences in gas-
trointestinal drug absorption (20). Therefore, there is strong
evidence that monitoring of plasma posaconazole concentra-
tions is indicated, although further evaluation of the benefit
of posaconazole TDM is certainly required.
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Figure 1 Structure of the antimycotic drugs posaconazole and itraconazole, the active metabolite hydroxyitraconazole, and the internal
standards ISTD1 (SCH 56984) and ISTD2 (R051012) that were used.
Currently, there is no consensus with respect to the ther-
apeutic range of posaconazole. Moreover, standardization of
assays for posaconazole quantification is another issue to be
addressed. Various HPLC assays for quantification of posa-
conazole have been reported, applying either UV detection
(11, 21, 22), fluorescence detection (FLD) (23) or mass spec-
trometric detection (LC-MS) (24–29). However, inter-labo-
ratory comparisons of different posaconazole assays have not
been reported at present, and there is currently only limited
availability of proficiency testing schemes.
An important issue affecting TDM methods are possible
interferences, either from co-administered drugs or from
metabolites of the parent drug. No evidence was found for
formation of pharmacologically active metabolites of posa-
conazole (21). Posaconazole is metabolized essentially via
glucuronidation by UDP-glucuronosyltransferase, resulting
in mono- and di-glucuronides as the primary metabolites in
plasma (25, 30). In-source fragmentation of labile glucuro-
nides is known for other drugs, such as mycophenolic acid
(31, 32), but no interfering metabolite peaks have been
described so far in LC-MS assays for posaconazole TDM.
In this article, observations concerning metabolite inter-
ferences during TDM of posaconazole are reported. Interfer-
ences became apparent during development of a new, fast
ultra performance liquid chromatography-tandem mass spec-
trometry (UPLC-MS/MS) method, and upon comparative
analysis with a LC-MS/MS method under evaluation at
another laboratory which showed significant quantitative dif-
ferences. In contrast, no systematic deviations were found
when compared with two independent HPLC methods using
fluorescence detection (FLD). Identification of the interfer-
ing compounds by precursor and product scan experiments
is described. Moreover, consequences for TDM of posaco-
nazole are discussed, and precautionary measures for pre-
vention of falsely increased results are suggested.
Materials and methods
UPLC-MS/MS
Chemicals and standards HPLC grade methanol (Merck, Darm-
stadt, Germany or Fisher Scientific, Schwerte, Germany) and HPLC
grade water (Mallinckrodt-Baker, Deventer, Netherlands) were used
as solvents. Formic acid and ammonium formate for mass spec-
trometry and ZnCl2 were obtained from Fluka/Sigma-Aldrich (Tauf-
kirchen, Germany). Matrix-matched standards and controls from
Chromsystems (Munich, Germany) were used for calibration and
quality control. Two internal standards were used: ISTD1 was pro-
vided by Schering-Plough/Essex Pharma (Munich, Germany) and
ISTD2 was obtained from Janssen Pharmaceuticals (Beerse,
Belgium).
Sample preparation The protein precipitation solution, consist-
ing of 40 mL MeOH, 10 mL ZnCl2 (0.2 M), and 350 mL of the
two internal standards (100 mg/L in methanol each), was prepared
fresh at least every 2 weeks. Three hundred microlitre of the metha-
nolic precipitation solution was added to 100 mL serum, vortexed
intensively and centrifuged 10 min at 13,000 g. Standards (three
levels plus blank calibrator) and controls were treated identically.
The supernatant was transferred to glass micro-vials and 10 mL
were injected for LC-MS analysis.
Instrumental LC-MS/MS analysis was performed using a Quat-
tro Premier XE equipped with an Acquity UPLC system (Waters,
Milford, MA, USA). A BEHC18 column (50=2.1 mm) with
1.7 mm particles was used in combination with a VanGuard pre-
column with the same material (Waters, Milford, MA, USA). The
flow rate was 0.6 mL/min and the column temperature was 608C.
Elution was achieved by linear gradient from 50% to 100% meth-
anol in 0.8 min. Hundred percentage methanol was held for another
0.8 min, followed by equilibration with the starting conditions. Total
run time was 2.6 min. The divert valve was switched to waste until
0.8 min. Both solvents contained 0.1% formic acid and 2 mM
ammonium formate. The latter is not necessary for the posaconazole
assay, but identical solvents and columns were used also for analysis
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of immunosuppressants. No deleterious effects from the addition of
ammonium salt were observed.
MS conditions were as follows: spray voltage 3.8 kV, desolvation
gas 500 L/h, cone gas 50 L/h, desolvation temperature 3508C,
source temperature 1008C, cone voltage 55 V. The following tran-
sitions were monitored for MRM (dwell time was 30 ms) in the
UPLC-MS/MS method A: 687.3)600.3 (ISTD1); 701.3)614.3
(posaconazole); 705.3)392.3 (itraconazole); 721.3)408.3
(hydroxyitraconazole); 733.3)460.3 (ISTD2). Alternative transi-
tions were used in UPLC-MS/MS method B for ISTD1
(687)669.3) and posaconazole (701.3)683.3). Collision energy
was 33 V for posaconazole and ISTD1, and 37 V for itraconazole,
hydroxyitraconazole and ISTD2. Identical conditions were used
for precursor and product scan experiments with a dwell time of
500 ms.
LC-MS/MS
The method was performed essentially as described previously (28).
It was comprised of a precipitation step, followed by online SPE
and isocratic elution into the MS.
HPLC-FLD
A commercial kit from Chromsystems (Munich, Germany) was used
for analysis of posaconazole, itraconazole and hydroxyitraconazole.
Sample preparation was performed according to the kit instructions.
Samples were analyzed in two different laboratories. In addition, an
in-house method with similar parameters was used for comparison.
Results
Evaluation of the UPLC-MS/MS method
A fast UPLC-MS/MS method for routine TDM of posa-
conazole with a run-time below 3 min was established. The
main benefits of UPLC are the enhanced duty-cycle in com-
bination with excellent separation efficiency and peak shape.
Validation confirmed good performance of the assay, cov-
ering the desired concentration range. Imprecision and recov-
ery was determined using spiked controls. Total imprecision
was determined to be 10.9% at 251 mg/L, 8.3% at 1015
mg/L and 7.3% at 4487 mg/L (for inter-assay and intra-assay
imprecision compare Table 1). The mean values of the three
concentration levels correspond to recoveries of 100.3%,
96.7% and 107.1%. The limit of detection was 12 mg/L
wdefined by a signal-to-noise (S/N) ratio of 3:1x, and the limit
of quantification was 37 mg/L (S/N 9:1). Linear response
was obtained between 25 mg/L and 3634 mg/L, with a
regression equation of ys(1.026"0.015)=–(4.914"6.299)
and R2s0.9948. Upon infusion experiments, reproducible
and gradient-dependant intensities were observed, with
almost constant analyte intensities in the elution range of
posaconazole, implicating minimized impact of ion suppres-
sion (compare Figure 2A).
Identification of glucuronide metabolites
Upon starting the UPLC-MS/MS method evaluation, two
earlier eluting peaks were observed in most patient samples
(compare Figure 3A), albeit with varying intensities. Addi-
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Figure 2 Example chromatograms (standards) of the new UPLC-MS/MS method and two of the assays used for comparative measurements.
(A) UPLC-MS; upper panel: MRM traces posaconazoleqISTD1qinfusion (ion suppression experiment); lower panel: MRM traces for
itraconazoleqhydroxyitraconazoleqISTD2; (B) LC-MS; MRM traces for posaconazole and ISTD1; (C) HPLC-FLD (Chromsystems).
tional, peaks were observed exclusively in post-dose patient
samples, but not in spiked calibrators or controls. Moreover,
a mean deviation of approximately 50% in patient samples
was found following comparative measurements during eval-
uation of a LC-MS/MS method adapted from Ref. (28).
Inspection of the chromatograms showed that peak width
was wider and peak shape was left side shifted.
Our suspicion was that additional peaks and quantitative
deviations could be caused by interference from conjugate
metabolites, namely glucuronides (25, 30). Obviously,
decomposition of metabolites and liberation of the parent
drug in the ion source leads to the appearance of additional
peaks in the MRM trace of posaconazole. In-source decom-
position of labile glucuronides is well-known, as for example
in the case of MMF/mycophenolate (31, 32). In order to
confirm this assumption, parent scan and precursor scan
experiments were performed on the UPLC-MS system. Traces
A and B in Figure 3 show parent scans of the most intense
fragment ions of posaconazole, m/z 614 and m/z 683. All
three peaks were indeed detected in both traces. The respec-
tive mass spectra at the retention times (RT) 0.91 min,
0.99 min and 1.03 min are shown in Figure 4A–C. The par-
ent mass of posaconazole (m/z 701) appears in all spectra,
but it is not the highest mass in the spectra of the two earlier
eluting peaks at RT 0.91 min and 0.99 min. Instead, another
precursor ion at m/z 877 is clearly visible, in accordance with
the expected mass of a glucuronide metabolite (mass differ-
ence of 176). This peak is absent in the spectrum obtained
at RT 1.03 min, the expected elution time of posaconazole.
A cross check was performed by product scan experi-
ments. Figure 3D shows the product scan of m/z 877, the
mass of the intact protonated glucuronide. The first two
peaks appear in this experiment exclusively, in accordance
with the assumption that only these are caused by glucuro-
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Figure 3 UPLC-MS chromatograms for a patient sample showing the detection of glucuronide metabolites. The peaks at RT 0.91 min
and RT 0.99 min correspond to posaconazole metabolites, whereas the peak at RT 1.03 min corresponds to the free drug. The peak at RT
1.44 min in trace E is not a posaconazole derivative, since the corresponding mass spectrum is completely different.
(A) MRM trace 701)614; (B) precursor scan of m/z 614; (C) precursor scan of m/z 683; (D) product scan of m/z 877 (glucuronide);
(E) product scan of m/z 701 (free drug); (F) MRM trace 701)614 at lower cone voltage (20 V instead of 55 V).
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Figure 4 MS/MS spectra from peaks in the chromatograms of Figure 3 which confirm that the additional peaks in the MRM trace are
caused by glucuronide metabolites.
(A) Mass spectrum at RT 0.91 min in the precursor scan of m/z 614 (trace B in Figure 3); (B) mass spectrum at RT 0.99 min in the
precursor scan of m/z 614 (trace B in Figure 3); (C) mass spectrum at RT 1.03 min in the precursor scan of m/z 614 (trace B in Figure
3); (D) mass spectrum at RT 0.91 min in the product scan of m/z 877 (trace D in Figure 3); (E) mass spectrum at RT 0.99 min in the
product scan of m/z 877 (trace D in Figure 3); (F) mass spectrum at RT 1.03 min in the product scan of m/z 701 (trace E in Figure 3).
nide metabolites. The corresponding mass spectra are depict-
ed in Figure 4D and E. In both cases, the main fragment is
the ion with m/z 701, which is the mass of the protonated
parent drug posaconazole. In addition, to the main peak,
fragment ions at m/z 614 and m/z 683 are also detected with
low intensity. These correspond to the most abundant frag-
ments of posaconazole, which have been selected for the
MRM experiments (compare spectrum in Figure 4F). These
observations give clear proof that the two earlier eluting
compounds are indeed posaconazole glucuronides. In con-
trast, the product ion scan of m/z 701 (Figure 3E) shows
nearly exclusively the posaconazole peak at RT 1.03, which
can be identified by its product mass spectrum depicted in
Figure 4F. However, small peaks are also visible at RT
0.91 min and 0.99 min, probably due to release of parent
drug from the respective glucuronides in the ion source,
which explains the additional peaks in the posaconazole
MRM trace. It should be noted that the peak at RT 1.44 is
not a posaconazole derivative, since the corresponding prod-
uct mass spectrum is completely different. The identification
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Figure 5 Correlation of UPLC-MS with HPLC assays (mean,
ns2, two laboratories) for determination of serum posaconazole
concentrations.
ISTD1 was used in case of UPLC-MS, whereas ISTD2 was used in
case of HPLC.
of glucuronides was supported also by chemical hydrolysis
experiments using NaOH which resulted in a significant
decrease in the metabolite peaks (factor 5–8 after 1.5 h incu-
bation at 378C).
Elimination of glucuronide interferences
Eliminating glucuronide interference is mandatory for the
correct determination of drug plasma concentrations. Inter-
fering peaks were clearly separated with UPLC-MS/MS, pre-
venting falsely increased results.
Alternatively, the influence of the metabolites can be
reduced significantly by choosing softer conditions in the ion
source. The main effect was observed by reducing the cone
voltage. This value is not only relevant for ion extraction,
but also influences the extent of ion desolvation and frag-
mentation in the ion source. Reduction of the cone voltage
from 55 V to 20 V led to almost complete disappearance of
the metabolite peaks (see Figure 3F). However, there was
decreased intensity of the posaconazole peak by a factor of
approximately 2–3 (compare Figure 3A). Since the noise lev-
el was reduced by a similar factor, the signal-to-noise ratio
was not compromised. Thus, even with insufficient separa-
tion, interferences can be minimized and correct quantifica-
tion is possible, provided soft conditions in the ion source
are chosen.
Baseline separation of posaconazole from the main meta-
bolite was also achieved using the LC-MS method by slight
modification of chromatographic parameters, including
smoothing and integration settings. This provided proof that
the glucuronide interference caused the asymmetrical peak
shape when applying the initial settings.
Assay comparison
After method adjustments, the correlation between the MS-
based methods (ns48) appeared to be significantly
improved with R2s0.9768 and linear regression of
ys(1.0726"0.0645)=q(1.8610"10.2335). However, the
second interference could not be separated without major
method changes, indicated by the residual mean deviation of
10.3% as assessed using the Bland-Altmann plot. Assay
modifications aiming to eliminate this remaining interference
were initiated.
It should be mentioned that choice of the internal standard
and MRM transition was essential for application of UPLC-
MS. Two different internal standards were tested, and the
itraconazole analogue (ISTD2) gave systematically higher
values (mean deviation 17%) compared to the posaconazole
analogue (ISTD1). The difference was even more pro-
nounced (mean deviation 30%) when compared to the
HPLC-FLD methods which use the identical ISTD2 (corre-
lations are shown in Supplementary Figure 1). Moreover,
higher imprecision was observed when using the transition
701)683 (loss of water, UPLC method B) instead of the
transition 701)614 (UPLC method A). This effect was not
observed when using online-SPE (method 2), which gener-
ally showed a better CV.
Six samples gave no detectable signal with HPLC-FLD.
Thus, 42 samples in the concentration range 31–1437 mg/L
were available for general method comparison between
HPLC and UPLC-MS (see Figure 5). The correlation was
excellent (R2s0.994) with linear regression of
ys(1.046"0.039)=q(2.756"7.446) and a mean deviation
of 4% (Bland-Altmann). Good correlation (R2)0.99) was
also obtained between two HPLC methods, even though the
in-house method utilizes aqueous instead of matrix-matched
standards. Basic validation data for all methods are shown
in Table 1, and detailed correlation data can be found in
Supplementary Table 1.
Discussion
The results of the present investigation substantiate the
importance of standardization of TDM assays. Appropriate
correlation was demonstrated after matrix-matched standards
become available. Moreover, the present example underlines
that it is necessary to be aware of pitfalls which may be
related to standards, internal standards or isobaric interfer-
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ences, such as co-administered drugs and metabolites of the
target molecule. In particular, it is critical that a sufficient
number of real-life patient samples be check for the occur-
rence of interference at an early stage of method evaluation.
Upon development of the posaconazole TDM methods, we
observed adverse effects due to (i) the choice of the internal
standard (ii) the MRM transition in UPLC-MS/MS and (iii)
in-source decay of analyte metabolites, namely glucuronides.
The itraconazole analogue (ISTD2) can be successfully
applied to HPLC analysis, but it is not suited to LC-MS.
These systematic deviations underline the need for almost
identical structures of analyte and internal standard to com-
pensate ionization effects. Unfortunately, the posaconazole
analogue (ISTD1) is currently no longer available. Hopeful-
ly, the growing demand for reliable LC-MS assays will even-
tually help solve this problem. Moreover, the choice of MRM
transition had a clear influence on method performance and
imprecision if no online-SPE was applied (see Table 1).
Apparently, the MRM transition 701)683 (loss of water) is
less specific compared to 701)614, as may be expected.
However, the most relevant observation concerns the
influence of metabolite interferences. The results are a strik-
ing example that conjugate metabolites, such as glucuronides
can appear in the MRM trace of the analyte due to in-source
decay and may thus impair TDM results. Usually, those inter-
ferences can be safely excluded by careful adjustment of
instrument conditions, such as chromatography, tuning para-
meters or peak processing settings.
In principal, the described interferences might even have
been predicted because the MS/MS spectra of the glucuro-
nides obtained during metabolism studies showed the mass
of the parent drug in the MS/MS spectra with high intensity.
However, none of the developed posaconazole TDM assays
published to date account for this effect. Short chromato-
graphy is preferred in TDM assays in order to enhance turn
around time, which leads to a higher risk of insufficient sep-
aration of metabolites. In contrast, extended chromatographic
separations are usually employed during drug discovery and
pharmacokinetic characterisation of drug candidates, which
minimizes the risk that metabolites are overlooked.
Online-SPE is another item which needs to be considered.
Online-SPE improves signal stability by reducing ion sup-
pression effects, and allows injection of larger sample vol-
umes and analyte enrichment. However, elution from the
SPE cartridge and subsequent chromatographic separation
and elution from the analytical column is often achieved
using isocratic conditions, since only one gradient pump is
necessary for this configuration. As a consequence, chro-
matographic resolution is inherently lower compared to
methods employing gradient separations, irrespective of
whether HPLC or UPLC are applied. Therefore, the risk of
overlooking metabolite interferences is greater with online-
SPE and isocratic elution.
Our observation underscores that in-source transformation
is an important potential pitfall in short LC-MS/MS methods
applied to TDM. Reliable elimination of interferences
depends to a great degree on individual instrument config-
uration and settings, such as MS tuning or chromatographic
parameters. Moreover, careful evaluation of the peak shape
of patient samples is mandatory and may help detect un-
identified interferences or other adverse effects. Also, if short
TDM methods are desired, it seems inevitable that samples
be thoroughly screened for the occurrence of metabolites
during early method evaluation, for example by analyzing a
sufficiently high number of patient samples with a longer LC
gradient than usually applied for TDM.
In summary, the presented fast UPLC-MS/MS method
allows for reliable TDM of posaconazole without interfer-
ence from co-eluting glucuronides. In addition, the results
are consistent with those obtained by independent methods.
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